JAM
PBYI icon

Jupiter Asset Management’s Puma Biotechnology PBYI Stock Holding History

Jupiter Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-645,871
Closed -$5.92M – 625
2021
Q2 		$5.92M Sell
645,871
-42,475
-6% -$430K 0.06% 272
2021
Q1 		$6.69M Sell
688,346
-40,094
-6% -$448K 0.07% 276
2020
Q4 		$7.47M Buy
728,440
+47,035
+7% +$476K 0.08% 256
2020
Q3 		$6.86M Buy
+681,405
New +$6.94M 0.07% 263

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Jupiter Asset Management's PBYI Position: Q3 2021 in Review

Jupiter Asset Management sold out of Puma Biotechnology (PBYI) in Q3 2021, closing a stake of 645,871 shares — an estimated $5.92M sold.

Jupiter Asset Management first reported a position in PBYI in Q3 2020 and held it in 4 quarters. The position peaked at $7.47M in Q4 2020. 115 funds tracked by Wall St. Rank hold PBYI as of Q3 2021.

  • Jupiter Asset Management reported no remaining Puma Biotechnology position as of Q3 2021 after selling out during the quarter.
  • Jupiter Asset Management sold 645,871 Puma Biotechnology shares in Q3 2021, an estimated $5.92M.
  • Jupiter Asset Management first reported a position in Puma Biotechnology in Q3 2020 and held it in 4 quarters.
  • Jupiter Asset Management's Puma Biotechnology position peaked at $7.47M in Q4 2020.
  • 115 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2021.

Based on Jupiter Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.